Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Specific treatment of multiple sclerosis

D H Silberberg1

  • 1University of Pennsylvania Medical Center in Philadelphia 19104, USA.

Clinical Neuroscience (New York, N.Y.)
|January 1, 1994
PubMed
Summary

Multiple sclerosis (MS) treatments primarily use immunotherapy, but a true "specific" therapy is lacking due to incomplete understanding of MS pathogenesis. Current options include anti-inflammatory and immunomodulatory drugs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adult human brain expresses four different molecular forms of neural cell adhesion molecules.

Neurochemistry international·2010
Same author

Immunologic characterization of oligodendroglia.

Neuroscience letters·2009
Same author

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED].

Neurology·2002
Same author

A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·1999
Same author

Corticosteroids and optic neuritis.

The New England journal of medicine·1993
Same author

2001 and beyond--what's ahead for neurology?

Annals of neurology·1992

Area of Science:

  • Neuroimmunology
  • Clinical Therapeutics

Background:

  • Multiple sclerosis (MS) management largely relies on immunotherapy.
  • Current treatments aim to manage symptoms and disease course but lack specificity due to incomplete understanding of MS pathogenesis.

Purpose of the Study:

  • To review the current landscape of immunotherapies for multiple sclerosis.
  • To categorize existing treatments and highlight commonly used agents.

Main Methods:

  • Literature review of immunotherapies for multiple sclerosis.
  • Categorization of treatments based on their primary mechanism of action (anti-inflammatory vs. immunomodulatory).

Main Results:

  • MS treatments are predominantly immunotherapies, often categorized as anti-inflammatory or immunomodulatory.
  • Many agents possess multiple actions, complicating simple classification.
  • Glucocorticoids are favored for acute attacks, while interferon-beta (IFN-beta) is used to reduce attack frequency and severity.

Conclusions:

  • The term "specific treatment" for MS is currently misleading.
  • A deeper understanding of MS pathogenesis is needed for truly targeted therapies.
  • Current therapeutic strategies involve managing inflammation and modulating the immune response.

Related Experiment Videos